Insider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Sells 10,382 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) Director Edward M. Md Kaye sold 10,382 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the transaction, the director now owns 148,253 shares of the company's stock, valued at approximately $1,285,353.51. This trade represents a 6.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Stoke Therapeutics Price Performance

STOK stock traded up $0.14 during trading on Monday, hitting $8.29. 964,264 shares of the company traded hands, compared to its average volume of 840,350. Stoke Therapeutics, Inc. has a 1 year low of $6.29 and a 1 year high of $17.58. The company has a market cap of $448.31 million, a PE ratio of -3.95 and a beta of 0.99. The stock's 50-day simple moving average is $9.47 and its 200 day simple moving average is $11.39.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.38. The firm had revenue of $22.61 million during the quarter, compared to analysts' expectations of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. Research analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Remove Ads

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, March 18th. Chardan Capital reissued a "buy" rating and issued a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Finally, HC Wainwright restated a "buy" rating and set a $47.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 19th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $23.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of STOK. Bank of New York Mellon Corp increased its stake in shares of Stoke Therapeutics by 1.4% in the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company's stock valued at $1,028,000 after purchasing an additional 1,330 shares in the last quarter. Graham Capital Management L.P. grew its holdings in Stoke Therapeutics by 8.5% in the fourth quarter. Graham Capital Management L.P. now owns 18,634 shares of the company's stock valued at $206,000 after purchasing an additional 1,453 shares during the period. Gilder Gagnon Howe & Co. LLC increased its position in shares of Stoke Therapeutics by 2.0% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company's stock valued at $1,021,000 after buying an additional 1,791 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Stoke Therapeutics by 6.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company's stock worth $414,000 after buying an additional 2,215 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of Stoke Therapeutics by 6.0% during the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company's stock valued at $545,000 after buying an additional 2,787 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.